Cancer patients who do research get newest drugs


February 23, 2009

USA Today

Cancer patients who research treatment options are three times more likely to get the newest drugs than patients who don't spend extra time learning about their condition, according to a study of 633 people with colorectal tumors.

Patients who sought information from the Internet, newspapers and magazines were more likely than others to have heard of the "targeted" therapies cetuximab, sold as Erbitux, and bevacizumab, sold as Avastin. But those who pursued second opinions from doctors as part of their research were the most likely actually to be prescribed these drugs, says the study led by the Dana-Farber Cancer Institute in Boston and published online today in Cancer ... Read More